Buckle R
Postgrad Med J. 1979;55 Suppl 5:71-8.
A group of 42 patients with gynaecomastia were treated with danazol. There were 31 adults and 11 cases of pubertal gynaecomastia. Dosage schedules in adults were 300-600 mg a day and in adolescents 200-300 mg a day. In the 31 adults, marked regression of gymaecomastia occurred in 18 and a moderate regression in 10, whilst in the 11 cases of puberty gynaecomastia, there was a marked regression in 7 and a moderate regression in 3. Plasma testosterone concentration fell in most patients. Follicle stimulating hormone (FSH) excretion in the urine seemed to fall to a greater extent than did the reduction in luteinizing hormone (LH). Yet the plasma concentration of both FSH and LH fell during treatment with danazol, whilst the pituitary responsiveness to luteinizing hormone releasing hormone (LRH) was blunted. Tests of other pituitary functions showed them to be unaffected.
一组42例男性乳房发育症患者接受了达那唑治疗。其中有31例成年人和11例青春期男性乳房发育症患者。成人的剂量方案为每日300 - 600毫克，青少年为每日200 - 300毫克。在31例成年人中，18例男性乳房发育症明显消退，10例中度消退；而在11例青春期男性乳房发育症患者中，7例明显消退，3例中度消退。大多数患者的血浆睾酮浓度下降。尿中促卵泡激素（FSH）排泄量下降的程度似乎比促黄体生成素（LH）的下降程度更大。然而，在达那唑治疗期间，FSH和LH的血浆浓度均下降，同时垂体对促黄体生成素释放激素（LRH）的反应迟钝。其他垂体功能测试表明它们未受影响。
